{"nctId":"NCT01996748","briefTitle":"Clinical Study to Assess the Efficacy and Safety of DF277 Compared to Placebo in the Treatment of Otic Eczema","startDateStruct":{"date":"2012-02"},"conditions":["Otic Eczema"],"count":135,"armGroups":[{"label":"DF277","type":"EXPERIMENTAL","interventionNames":["Drug: DF277"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"DF277","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 12 years or older\n* Clinical diagnosis of otic eczema suitable for local treatment\n\nExclusion Criteria:\n\n* Other diseases.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Analysis of the Itching Change at the End of Treatment.","description":"The analysis of the itching change at the end of treatment (mean itching on days 4-8 compared to baseline). Itching was assessed on a 4 point ordinal scale; 0=absent, 1=mild, 2=moderate, 3=severe","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.63","spread":"0.82"},{"groupId":"OG001","value":"-1.25","spread":"0.72"}]}]}]},{"type":"SECONDARY","title":"Change in Signs/ Symptoms","description":"\\- Change in itching at follow-up (mean itching on days 9-15 compared to baseline).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.80","spread":"0.81"},{"groupId":"OG001","value":"-1.32","spread":"0.77"}]}]}]},{"type":"SECONDARY","title":"Change in Mean Global Scores of Otoscopic Signs (Erythema, Edema and Scaling) at the End of Treatment (Day 8) Compared to Baseline (Day 1).","description":"Analysis of the change on global scores of otoscopic signs at the end of treatment (mean global scores of otoscopic signs on day 8 compared to baseline).\n\nErythema, edema and scaling were assessed on a 4 point ordinal scale; 0=absent, 1=mild, 2=moderate, 3=severe.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.21","spread":"0.68"},{"groupId":"OG001","value":"-0.78","spread":"0.68"}]}]}]},{"type":"SECONDARY","title":"Change in Mean Global Scores of Otoscopic Signs (Erythema, Edema and Scaling) at the End of Follow-up (Day 15) Compared to Baseline (Day 1).","description":"Analysis of the change on global scores of otoscopic signs at the end of treatment (mean global scores of otoscopic signs on day 15 compared to baseline).\n\nErythema, edema and scaling were assessed on a 4 point ordinal scale; 0=absent, 1=mild, 2=moderate, 3=severe.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.20","spread":"0.68"},{"groupId":"OG001","value":"-0.77","spread":"0.72"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":66},"commonTop":["Ear discomfort","Otitis externa"]}}}